[Featured Stock] Clinomics Rises on Expectations for Gene Big Data-Based NFT and Metaverse Business

[Asia Economy Reporter Minwoo Lee] Clinomics' stock price is on the rise. The news that the company is promoting a non-fungible token (NFT) business utilizing genetic big data has drawn attention, creating expectations that it could expand its scope to the metaverse (extended virtual world) in the future.

As of 2:59 PM on the 3rd, Clinomics' stock price recorded 13,600 KRW, up 5.02% compared to the previous day. This appears to be driven by anticipation of the convergence between genetic big data, NFTs, and the metaverse. Earlier that day, EDGC (Eone Diagnomics Genome Center) announced that it would supply its genome big data engine, Yuhoo, to a consortium called the ‘AI Human Metaverse Project,’ which includes seven companies such as Maxst, an augmented reality (AR) and virtual reality (VR) related company, and Class Soft, a game platform and content developer. Following EDGC’s record of hitting the upper price limit, Clinomics also attracted attention in the same context.

Previously, at the end of last month, Clinomics announced plans to launch a 'Bio Arts' business that converts genome big data into NFTs and distributes them via blockchain. As part of this NFT business, Park Jonghwa, Clinomics’ Chief Technology Officer (CTO), and designer Byun Hani decoded and analyzed the Korean tiger genome for the first time in the world and converted it into an NFT, which was then released on the NFT trading platform OpenSea.

In the long term, Clinomics plans to build a blockchain-based personal big data platform, virtualize personal health big data, reduce the costs of individual genetic testing and medical expenses, and provide personalized health solutions.